How many courses of PD1 treatment are needed depends on the type of tumor, the severity of the disease and the patient’s physical condition, which should be analyzed on a case-by-case basis and should not be generalized. PD1 treatment is a kind of immunotherapy with a wide range of application, but it does not target a certain kind of cancer, and the overall efficiency is about 50%. If patients have advanced metastatic tumors and other treatment modalities are less effective, they can try PD1 therapy and if it is effective, it can be applied for a long time. The specific course of PD1 treatment cannot be specified clinically, so patients are recommended to go to the oncology department of regular hospitals for examination and professional doctors to formulate rationalized treatment plans according to patients’ specific conditions. In addition, cancer patients are recommended to adopt an integrated treatment approach to prolong survival, reduce pain and improve their quality of life.